source
- Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type CBeren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
- Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-SSellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…